Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Recce Pharmaceuticals Ltd. ( (AU:RCE) ) has shared an update.
Recce Pharmaceuticals Ltd announced that its RECCE® 327 Topical Gel (R327G) has shown statistically significant positive efficacy against Methicillin-resistant Staphylococcus aureus (MRSA) and Pseudomonas aeruginosa in rat infection models. The study demonstrated that R327G not only reduced bacterial load significantly but also accelerated wound healing compared to the standard antibiotic Soframycin. This development supports ongoing collaboration with the U.S. Department of Defense, including a US$2M grant and a Cooperative Research and Development Agreement with the US Army Medical Research Institute of Infectious Diseases. The results suggest that R327G could offer a more effective and convenient treatment option for burn wounds, potentially benefiting patients, clinicians, and healthcare economics.
More about Recce Pharmaceuticals Ltd.
Recce Pharmaceuticals Ltd is a leading developer in the pharmaceutical industry, specializing in a new class of synthetic anti-infectives. The company focuses on addressing antibiotic-resistant pathogens, which are a significant threat to human health.
Average Trading Volume: 152,542
Technical Sentiment Signal: Sell
Current Market Cap: A$108.4M
Find detailed analytics on RCE stock on TipRanks’ Stock Analysis page.